Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06005103

A Randomized Clinical Trial Comparing Active Versus Sham T-PEMF Headband Treatment for Depression

An 8-week, two-armed, randomized-controlled trial that examines the antidepressant effect of treatment with transcranial pulsed electromagnetic fields (T-PEMF) in patients diagnosed with moderate to severe depression using using a new device, the MoodHeadBand (MHB).

The participants will use an active or placebo MHB for 30 minutes daily for 8 weeks.

Additionally, the following research questions will be answered:

1. If there is a positive effect on the patients' emotional and non-emotional cognition after 8 weeks of active treatment compared to the sham group and if possible early changes in the emotional cognition can predict the treatment response after 8 weeks of treatment.

1. If the T-PEMF treatment provides improvement in restorative sleep after 8 weeks of treatment

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Psychiatric Center Copenhagen

Frederiksberg, Capital Region, 2600, Denmark

Location status: Recruiting

Location contact

Nana B. Sørensen, MD

CONTACT

[email protected]

23 26 70 81 ext. +45

Nana Brandborg B. Sørensen, MD

SUB_INVESTIGATOR

About this study

The purpose of this study is to clarify whether daily treatment over eight weeks with weak pulsating electromagnetic fields (T-PEMF) can achieve a safe effect on depression compared to the same treatment with a placebo T-PEMF. The study will furthermore explore possible effects on cognition and the hypothesized sleep-ameliorating effect of T-PEMF. Previous Danish studies have shown a significant antidepressant effect of other T-PEMF devices in the treatment of patients with depression.

The study is designed as a blinded, randomized study where active treatment is compared with inactive (placebo) treatment. At the same time, possible side effects in the use of the headband (MoodHeadBand, MHB) are investigated.

The project was initiated June 2024. Patients consecutively referred are asked after an initial interview whether they wish to participate in the study. If they give informed consent to this, they will be randomized to active or placebo treatment. The treatment itself takes place at home, 30 minutes once a day, for 8 weeks. "Treatment as usual" takes place in parallel to the study treatment, and consists of psychotherapy in a group or individually and antidepressive medications. Follow-ups will be conducted weekly either as visits at the clinic, via videocall or as telephone calls. The participants will receive weekly surveys they are encouraged to fill out prior to the weekly follow-ups. The severity of the depression, including its symptomatology will be examined weekly during the study, the cognitive test-battery is applied at baseline, week 1 and at the final visit, the patients sleep-pattern and possible disturbances are examined via the weekly surverys.

No significant side effects have been registered when using the same type of electromagnetic field treatment in the previous Danish studies. It has also been shown that it is possible to carry out the treatment at home without significant problems.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Meeting the diagnostic criteria for moderate to severe depressive episode without psychotic symptoms according to the International Classification of Diseases and Related Health Problems 10th Revision (ICD-10)(The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research 1993).
  • Female participants: Females in the fertile age must deliver a negative pregnancy test, or previously have been sterilized.
  • Female fertile participants: They must use safe contraceptive methods to be included in the study, and during the whole study.
  • Has given written, informed consent to the trial.

Exclusion criteria

  • Inability to speak or understand the Danish language.
  • A current high risk of suicide (a score of 2 or more on the HAM-D-17 item 3).
  • A co-morbid substance dependence.
  • Bipolar affective disorder.
  • Psychotic illness.
  • Dementia.
  • Other diagnoses of organic brain disease.
  • The participant has any kind of implant, e.g. pacemakers or cochlear implants.
  • Female participants: Pregnancy

Treatment and study plan

Treatment with MoodHeadBand (T-PEMF treatment)

Device

The patients will receive treatment with T-PEMF using a headband containing 20 coils placed symmetrically around the head of the patient. The device delivers 55 Hz magnetic field. Duration of treatment is 30 minutes once a day for 8 weeks.

Inactive treatment with MoodHeadBand (Placebo)

Device

Patients will use an identical device, which does not deliver T-PEMF treatment. The patients will use the headband as the active group for 30 minutes, once a day, for 8 weeks.

Primary outcomes

  1. Inventory of Depressive Symptomatology (Self-Report) (IDS-SR)

    Time frame: 8 weeks

    The IDS-SR is a 30-item self-report scale for measuring depressive symptoms, with satisfying psychometric features and good correlations with Hamilton-D17 (HAM-D17).

Secondary outcomes

  1. Hamilton-D17 (HAM-D17)

    Time frame: 8 weeks

    A scale measuring depressive symptoms. Will be applied at baseline and at the end point

  2. Hamilton-D6 (HAM-D6)

    Time frame: 8 weeks

    A scale measuring depressive symptoms. Will be applied at baseline and at the end point.

  3. Quick Inventory of Depressive Symptomatology

    Time frame: 8 weeks

    A quick-version of the IDS questionnaire, that consists of 16 questions. Patients fill this assesment on a weekly basis during the study.

  4. WHO-5

    Time frame: 8 weeks

    This Well-Being Index consists of five items that are scored on a frequency response scale from "none of the time" (0) to "all of the time" (5).

  5. Facial Expression and Recognition Test (FERT)

    Time frame: 8 weeks

    A test that assesses the patients recognition of - and attention to facial expressions as a part of the cognitive test battery that explores the patients "hot" cognition.

  6. Emotional Categorization and Memory Test (ECMT)

    Time frame: 8 weeks

    A test that assesses the patient' self-referential memory with emotion laded words as a part of the cognitive test battery that explores the patients' "hot" cognition.

  7. Screening of cognitive impairment in Psychiatry (SCIP)

    Time frame: 8 weeks

    A screening tool used to assess cognitive performance in psychiatric patients. The test includes List learning, delayed list learning, verbal fluency, visuomotor tracking tests. Explores the patients' "cold" cognitive mechanisms.

  8. Trail Making Test B (TMT-B)

    Time frame: 8 weeks

    A test that assesses the patients' visual attention and ability to switch tasks. Explores the patients' "cold" cognitive mechanisms.

  9. Sleep diary

    Time frame: 8 weeks

    The diary explores the patients sleep pattern and quality of sleep.

  10. Udvalget for Kliniske Undersøgelser scale (UKU-24)

    Time frame: 8 weeks

    Side effects are assessed by the UKU-24 scale, including free text comments. Side effects will be assesed at week 1, 2, 4, 6 and at the end point.

Study contacts

Contact information is provided by the study sponsor or research team.

Martin B. Jørgensen, MD DMSc

CONTACT

[email protected]

23328669 ext. +45

Nana B Sørensen, MD

CONTACT

[email protected]

26356751 ext. +45

Sponsors and collaborators

Lead sponsor

Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital

Other

Collaborators

  • Danish Medical Association
  • Doctor Gerhard Linds scholarship
  • Innovation Fund Denmark
  • MoodHeadBand Aps

Registry information

Official study title

Active Versus Sham Transcranial Pulsed Electromagnetic Field Headband Treatment for Major Depression: a Study Protocol for a Double-blinded Randomized Trial

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Aug 22, 2023
Registry last updated
Aug 26, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.